



January 16, 2014

To whom it may concern:

Company name: Nichi-Iko Pharmaceutical Co., Ltd.  
(Securities code: 4541 Tokyo Stock Exchange, First Section)  
Representative: Yuichi Tamura  
President and CEO  
Contact: Noboru Inasaka  
Managing Executive Officer and General  
Manager of Management Division  
(Tel: 076-432-2121)

### Notice Concerning Transfer of Major Shareholder

Nichi-Iko Pharmaceutical Co., Ltd. (the "Company") hereby announces that on January 15, 2014, there was a transfer of major shareholder. The details are as follows.

#### 1. Background of transfer

TAMURA Co., Ltd. was allotted 4,285,361 of the Company's Stock Acquisition Rights No. 5 in regard to the commitment-type rights offering, which was announced by the Company in the "Notice Concerning the Commitment-type Rights Offering (Allotment of Listing-type Stock Acquisition Rights without Contribution)", dated November 27, 2013. TAMURA Co., Ltd. transferred 3,837,200 of such Stock Acquisition Rights to Taku Co., Ltd., a wholly owned subsidiary of TAMURA Co. Ltd. TAMURA Co., Ltd. and Taku Co., Ltd. have reported that they have exercised all of such Stock Acquisition Rights allotted to TAMURA Co., Ltd., as was announced by the Company in the "Notice Concerning the Status of Exercise of Nichi-Iko Pharmaceutical Co., Ltd. Stock Acquisition Rights No. 5 by Existing Shareholders, etc.", dated January 14, 2014. Furthermore, due to the exercise of the Company's Stock Acquisition Rights No. 5 by the other holders of the Stock Acquisition Rights up to January 14, 2014, the total number of voting rights of the Company increased, which reduced the voting percentage of TAMURA Co., Ltd. As a result, TAMURA Co., Ltd. is no longer a major shareholder of the Company.

#### 2. Outline of the transferred major shareholder

(1) Name	TAMURA Co., Ltd.
(2) Address	11-17, Inarimotomachi 1-chome, Toyama City, Toyama
(3) Name and Title of Representative	Yuichi Tamura, Representative Director
(4) Description of Business	securities holding, real estate leasing
(5) Amount of Capital	26 million yen

3. Number of voting rights (number of shares) held by such Shareholder and number of voting rights as a percentage of total voting rights, before and after the transfer

	Number of voting rights (Number of shares held)	Number of voting rights as a percentage of total voting rights*	Rank as major shareholder
Before the transfer (as of December 9, 2013)	42,853 (4,285,361 shares)	10.76%	1st
After the transfer	45,101 (4,510,141 shares)	9.73%	1st

\* number of shares without voting rights deducted from total number of issued shares, as of December 9, 2013:

887,217 shares

total number of issued shares as of December 9, 2013: 40,729,417 shares

number of shares without voting rights deducted from total number of issued shares, as of January 15, 2014:

917,649 shares

total number of issued shares as of January 15, 2014: 47,289,049 shares

4. Future prospects

The transfer in the major shareholder has no impact on the Company's performance.

END